D. Boral Capital reaffirmed their buy rating on shares of Medicus Pharma (NASDAQ:MDCX - Free Report) in a report issued on Thursday,Benzinga reports. The brokerage currently has a $27.00 target price on the stock.
A number of other equities analysts also recently commented on the company. D Boral Capital upgraded Medicus Pharma to a "strong-buy" rating in a report on Monday, April 14th. Maxim Group increased their target price on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen lowered shares of Medicus Pharma from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.50.
Read Our Latest Stock Report on Medicus Pharma
Medicus Pharma Stock Up 3.5%
Shares of MDCX traded up $0.09 during mid-day trading on Thursday, reaching $2.64. The company had a trading volume of 343,230 shares, compared to its average volume of 119,952. Medicus Pharma has a fifty-two week low of $1.80 and a fifty-two week high of $8.94. The company's fifty day simple moving average is $4.51.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). As a group, equities research analysts anticipate that Medicus Pharma will post -1.14 earnings per share for the current year.
Insider Buying and Selling
In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $7.72, for a total value of $579,000.00. Following the transaction, the insider now owns 3,248,741 shares in the company, valued at approximately $25,080,280.52. The trade was a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Hedge Funds Weigh In On Medicus Pharma
Several large investors have recently modified their holdings of the stock. Interchange Capital Partners LLC acquired a new stake in shares of Medicus Pharma during the 4th quarter worth approximately $3,628,000. Private Advisor Group LLC bought a new position in Medicus Pharma during the 1st quarter worth $211,000. Finally, Armistice Capital LLC bought a new position in Medicus Pharma during the 1st quarter worth $4,710,000.
About Medicus Pharma
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Recommended Stories
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
